Last reviewed · How we verify
Antihypertensive Agents
At a glance
| Generic name | Antihypertensive Agents |
|---|---|
| Also known as | Nifedipine and hydrochlorothiazide |
| Sponsor | University Hospital, Caen |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension (NA)
- Orthostatic And Postprandial Hypotension In Hospitalized Older Adults (HOPE65)
- Use of a Cloud-connected Remote Blood Pressure Monitoring Program During the Postpartum Period for Hypertensive Women
- CENtral Blood Pressure Targeting: A Pragmatic RAndomized Pilot triaL in Advanced Chronic Kidney Disease (NA)
- BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (NA)
- REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study (NA)
- The GUARDIAN Pilot Trial (NA)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antihypertensive Agents CI brief — competitive landscape report
- Antihypertensive Agents updates RSS · CI watch RSS
- University Hospital, Caen portfolio CI